Evidence map›Paper›PMID 36917628›Full record

ArticleStem cells translational medicine2023

A Novel Approach for Determining the Critical Quality Attributes of Mesenchymal Stem Cells by Specifying Cell Population With Replication Potential.

Takako Yamamoto, Mao Arita, Takashi Tamura, Miho Saito, Hirohito Katayama, Hirotaka Kuroda, Takashi Suzuki, Shin Kawamata

Open access · goldFull text read
In one paragraph

Article in Stem cells translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Takako YamamotoR&D Center for Cell Therapy, Foundation for Biomedical Research and Innovation, Kobe, Japan.ORCID 0000-0002-1877-0359
Mao AritaR&D Center for Cell Therapy, Foundation for Biomedical Research and Innovation, Kobe, Japan.
Takashi TamuraR&D Center for Cell Therapy, Foundation for Biomedical Research and Innovation, Kobe, Japan.
Miho SaitoR&D Center for Cell Therapy, Foundation for Biomedical Research and Innovation, Kobe, Japan.
Hirohito KatayamaNovartis Pharma KK, Tokyo, Japan.
Hirotaka KurodaShimadzu Corp., Kyoto, Japan.
Takashi SuzukiShimadzu Corp., Kyoto, Japan.
Shin KawamataR&D Center for Cell Therapy, Foundation for Biomedical Research and Innovation, Kobe, Japan.
Foundation for Biomedical Research and Innovation · JPShimadzu (Japan) · JPNovartis (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We introduce a novel approach to determine the critical quality attributes (CQAs) of mesenchymal stem cells (MSCs) expected to exert immunosuppressive effects. MSCs retained homeostatic replication potentials, such as sustainable growth and consistent cell morphology as a population, in early passages, but lost them in late passages. Characteristic surface markers of MSCs (ie, CD73, CD90, and CD105) were no longer expressed at 2 weeks after subcutaneous transplantation into NOG mice when MSCs from late passages were transplanted, but not when MSCs from early passages were transplanted, suggesting that the biological effects of the MSCs differed according to the timing of cell harvesting and highlighting the importance of specifying MSCs that retained homeostatic features to define the CQAs. The homeostatic features of MSCs related to the balance of the redox system, nutrient requirements, and mitochondrial function were also observed until a certain passage. Therefore, we could define the CQAs of MSCs related to manufacturing by selecting process parameters (PPs) underlying the homeostatic features of MSCs and measuring these PPs quantitatively to specify the cell population with homeostatic features by limiting the passage number. The validity of the PPs stipulated in our pilot study was verified using an SKG murine arthritis model, and critical PPs (CPPs) were then selected among the PPs. Thus, CQAs related to manufacturing in the developmental phase could be defined by the CPPs in this manner, and the concept of CQAs could be refined continuously toward commercial manufacturing.

Indexed as

Mesenchymal Stem CellsAnimalsCell DifferentiationCell ProliferationCells, CulturedMicePilot Projectscritical process parametercritical quality attributemesenchymal stem cellsmitochondrial functionRedox system

Identifiers

PMID36917628
PMCPMC10021496
OpenAlexW4324128531

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read55
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.